Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 3
2004 5
2005 3
2006 7
2007 5
2008 3
2009 2
2010 4
2011 10
2012 12
2013 7
2014 13
2015 16
2016 14
2017 14
2018 10
2019 9
2020 20
2021 13
2022 11
2023 7
2024 7
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

173 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group. Kappos L, et al. N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089952 Free article. Clinical Trial.
The annualized relapse rate was 0.18 with 0.5 mg of fingolimod, 0.16 with 1.25 mg of fingolimod, and 0.40 with placebo (P<0.001 for either dose vs. placebo). ...Causes of study discontinuation and adverse events related to fingolimod included bradycardia a …
The annualized relapse rate was 0.18 with 0.5 mg of fingolimod, 0.16 with 1.25 mg of fingolimod, and 0.40 with placebo (P<0 …
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
Lublin F, Miller DH, Freedman MS, Cree BAC, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, Merschhemke M, Li B, Putzki N, Liu FC, Häring DA, Kappos L; INFORMS study investigators. Lublin F, et al. Lancet. 2016 Mar 12;387(10023):1075-1084. doi: 10.1016/S0140-6736(15)01314-8. Epub 2016 Jan 28. Lancet. 2016. PMID: 26827074 Free article. Clinical Trial.
Patients were initially assigned to fingolimod 1.25 mg per day or placebo (cohort 1); however, after a protocol amendment on Nov 19, 2009, patients were switched in a masked manner to fingolimod 0.5 mg, whereas those on placebo continued on matching placebo. ...FIND …
Patients were initially assigned to fingolimod 1.25 mg per day or placebo (cohort 1); however, after a protocol amendment on Nov 19, …
Fingolimod for relapsing-remitting multiple sclerosis.
La Mantia L, Tramacere I, Firwana B, Pacchetti I, Palumbo R, Filippini G. La Mantia L, et al. Cochrane Database Syst Rev. 2016 Apr 19;4(4):CD009371. doi: 10.1002/14651858.CD009371.pub2. Cochrane Database Syst Rev. 2016. PMID: 27091121 Free PMC article. Review.
BACKGROUND: Fingolimod was approved in 2010 for the treatment of patients with the relapsing-remitting (RR) form of multiple sclerosis (MS). ...The risk of fingolimod discontinuation was significantly higher compared to placebo for the dose 1.25 mg at 24 months (RR …
BACKGROUND: Fingolimod was approved in 2010 for the treatment of patients with the relapsing-remitting (RR) form of multiple sclerosi …
The efficacy and safety of fingolimod in patients with relapsing multiple sclerosis: A meta-analysis.
Yang T, Tian X, Chen CY, Ma LY, Zhou S, Li M, Wu Y, Zhou Y, Cui YM. Yang T, et al. Br J Clin Pharmacol. 2020 Apr;86(4):637-645. doi: 10.1111/bcp.14198. Epub 2020 Feb 8. Br J Clin Pharmacol. 2020. PMID: 31869429 Free PMC article. Review.
Fingolimod also exhibited a favorable performance on other magnetic resonance imaging outcomes and improved the quality of life in patients. No significant difference was noted in the prevalence of adverse events between the fingolimod treatment group and the placeb …
Fingolimod also exhibited a favorable performance on other magnetic resonance imaging outcomes and improved the quality of life in pa …
The efficacy and safety of fingolimod plus standardized treatment versus standardized treatment alone for acute ischemic stroke: A systematic review and meta-analysis.
Bai P, Zhu R, Wang P, Jiang F, Zhen J, Yao Y, Zhao C, Liang Z, Wang M, Liu B, Li M, Li N, Yuan J. Bai P, et al. Pharmacol Res Perspect. 2022 Jun;10(3):e00972. doi: 10.1002/prp2.972. Pharmacol Res Perspect. 2022. PMID: 35585652 Free PMC article.
Acute ischemic stroke (AIS) is the most common type of stroke. Fingolimod is a sphingosine analog that acts on sphingosine-1-phosphate receptors (S1PR). ...The Fingolimod plus standard treatment group decreased infarct growth and improved clinical function than the …
Acute ischemic stroke (AIS) is the most common type of stroke. Fingolimod is a sphingosine analog that acts on sphingosine-1-phosphat …
Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.
Chitnis T, Arnold DL, Banwell B, Brück W, Ghezzi A, Giovannoni G, Greenberg B, Krupp L, Rostásy K, Tardieu M, Waubant E, Wolinsky JS, Bar-Or A, Stites T, Chen Y, Putzki N, Merschhemke M, Gärtner J; PARADIGMS Study Group. Chitnis T, et al. N Engl J Med. 2018 Sep 13;379(11):1017-1027. doi: 10.1056/NEJMoa1800149. N Engl J Med. 2018. PMID: 30207920 Free article. Clinical Trial.
The adjusted annualized relapse rate was 0.12 with fingolimod and 0.67 with interferon beta-1a (absolute difference, 0.55 relapses; relative difference, 82%; P<0.001). ...Adverse events, excluding relapses of multiple sclerosis, occurred in 88.8% of patients who receive …
The adjusted annualized relapse rate was 0.12 with fingolimod and 0.67 with interferon beta-1a (absolute difference, 0.55 relapses; r …
Prognostic significance of neurofilament light in Fingolimod therapy for Multiple Sclerosis: A systemic review and meta-analysis based on randomized control trials.
Ashkar A, Baig MMA, Arif A, Ali MM, Yousuf F, Ashkar R. Ashkar A, et al. Mult Scler Relat Disord. 2023 Jan;69:104416. doi: 10.1016/j.msard.2022.104416. Epub 2022 Nov 17. Mult Scler Relat Disord. 2023. PMID: 36495843 Review.
Moreover, effect of Fingolimod on NfL levels was analysed qualitatively. RESULTS: Five Randomized Controlled Trials were used in the study. ...CONCLUSION: The results of our meta-analysis and systematic review demonstrated statistically significant effect of NfL as a progn …
Moreover, effect of Fingolimod on NfL levels was analysed qualitatively. RESULTS: Five Randomized Controlled Trials were used in the …
Real-world persistence with fingolimod for the treatment of multiple sclerosis: A systematic review and meta-analysis.
Kantor D, Johnson K, Vieira MC, Signorovitch J, Li N, Gao W, Koo V, Duchesneau E, Herrera V. Kantor D, et al. J Neurol Sci. 2018 May 15;388:168-174. doi: 10.1016/j.jns.2018.03.018. Epub 2018 Mar 10. J Neurol Sci. 2018. PMID: 29627016
OBJECTIVE: To systematically review reports of fingolimod persistence in the treatment of relapsing-remitting multiple sclerosis (RRMS) across data sources and practice settings, and to develop a consensus estimate of the 1-year real-world persistence rate. ...CONCLUSIONS: …
OBJECTIVE: To systematically review reports of fingolimod persistence in the treatment of relapsing-remitting multiple sclerosis (RRM …
Incidence of cancer in patients with multiple sclerosis (MS) who were treated with fingolimod: A systematic review and meta-analysis.
Askari M, Mirmosayyeb O, Ghaffary EM, Ghoshouni H, Shaygannejad V, Ghajarzadeh M. Askari M, et al. Mult Scler Relat Disord. 2022 Mar;59:103680. doi: 10.1016/j.msard.2022.103680. Epub 2022 Feb 9. Mult Scler Relat Disord. 2022. PMID: 35176641 Review.
BACKGROUND: Fingolimod is a sphingosine-1-phosphate-receptor modulator that is used for the relapsing form of MS. ...Totally, 64,135 patients with MS who received fingolimod were enrolled. The total number of patients with cancer was 2561. The pooled incidence of ca …
BACKGROUND: Fingolimod is a sphingosine-1-phosphate-receptor modulator that is used for the relapsing form of MS. ...Totally, 64,135 …
Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
Singer B, Ross AP, Tobias K. Singer B, et al. Int J Clin Pract. 2011 Aug;65(8):887-95. doi: 10.1111/j.1742-1241.2011.02721.x. Epub 2011 Jun 16. Int J Clin Pract. 2011. PMID: 21679286 Review.

In FREEDOMS, there was a 55% decrease in ARR at 2 years with fingolimod 0.5 mg vs. placebo (0.18 vs. 0.40; p < 0.001). Risk of disability progression, confirmed at 3 months, was also reduced by 30% over the 2-year study period with fingolimod vs. placebo (p = 0.0

…

In FREEDOMS, there was a 55% decrease in ARR at 2 years with fingolimod 0.5 mg vs. placebo (0.18 vs. 0.40; p < 0.001). Risk of dis

…
173 results

Searches related to "fingolimod"